Farther Finance Advisors LLC Has $230,000 Stock Position in GSK PLC Sponsored ADR (NYSE:GSK)

Farther Finance Advisors LLC raised its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 50.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,085 shares of the pharmaceutical company’s stock after purchasing an additional 2,030 shares during the quarter. Farther Finance Advisors LLC’s holdings in GSK were worth $230,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in GSK. Sierra Ocean LLC acquired a new stake in GSK during the fourth quarter valued at approximately $32,000. Parkside Financial Bank & Trust boosted its holdings in shares of GSK by 470.1% in the 4th quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company’s stock worth $34,000 after acquiring an additional 818 shares in the last quarter. Lee Danner & Bass Inc. acquired a new position in shares of GSK in the 4th quarter worth approximately $39,000. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of GSK in the 4th quarter worth approximately $40,000. Finally, Atala Financial Inc acquired a new position in shares of GSK in the 4th quarter worth approximately $45,000. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Stock Performance

Shares of GSK stock opened at $38.66 on Thursday. The firm has a fifty day moving average of $38.41 and a two-hundred day moving average of $36.76. The stock has a market capitalization of $79.23 billion, a price-to-earnings ratio of 19.93, a PEG ratio of 1.39 and a beta of 0.52. GSK PLC Sponsored ADR has a 52 week low of $31.72 and a 52 week high of $44.67. The company has a debt-to-equity ratio of 1.21, a quick ratio of 0.58 and a current ratio of 0.87.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, beating the consensus estimate of $1.08 by $0.05. The company had revenue of $10.06 billion during the quarter, compared to analysts’ expectations of $7.52 billion. GSK had a net margin of 9.89% and a return on equity of 48.82%. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.43 EPS. As a group, equities research analysts predict that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be given a $0.4216 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.36%. This is a boost from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio is currently 87.11%.

Analyst Ratings Changes

GSK has been the topic of several recent analyst reports. Wall Street Zen downgraded GSK from a “buy” rating to a “hold” rating in a report on Friday, May 30th. Berenberg Bank reaffirmed a “hold” rating on shares of GSK in a report on Tuesday, June 3rd. Hsbc Global Res raised GSK to a “strong sell” rating in a report on Monday, April 28th. Finally, BNP Paribas started coverage on GSK in a report on Tuesday, April 15th. They set a “neutral” rating and a $35.25 price objective on the stock. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, GSK currently has a consensus rating of “Hold” and a consensus target price of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.